Jacobs Levy Equity Management
AMLX icon

Jacobs Levy Equity Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jacobs Levy Equity Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,091
Closed -$273K – 1031
2025
Q1 		$273K Sell
77,091
-237,848
-76% -$846K ﹤0.01% 993
2024
Q4 		$1.19M Sell
314,939
-163,501
-34% -$769K ﹤0.01% 689
2024
Q3 		$1.55M Sell
478,440
-110,671
-19% -$249K 0.01% 648
2024
Q2 		$1.12M Buy
+589,111
New +$1.14M ﹤0.01% 707

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Jacobs Levy Equity Management's AMLX Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 77,091 shares — an estimated $273K sold.

Jacobs Levy Equity Management first reported a position in AMLX in Q2 2024 and held it in 4 quarters. The position peaked at $1.55M in Q3 2024. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • Jacobs Levy Equity Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 77,091 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $273K.
  • Jacobs Levy Equity Management first reported a position in Amylyx Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Amylyx Pharmaceuticals position peaked at $1.55M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.